ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Jemincare and Johnson & Johnson side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

JemincareJohnson & Johnson
studies on the registry373,709
open to participants now30146
phase 3 studies under way395
reach primary completion within a year688
programswith a study of their own in two years956+4 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseJemincareJohnson & Johnson
Phase 1

Jemincare: 5 of its 9 programs at phase 1

  1. JMKX000197phase 1
  2. JMKX003948phase 1
  3. Amiodaronephase 1
  4. JMKX005425phase 1
  5. JY1001phase 1
56%

Johnson & Johnson: 26 of its 56 programs at phase 1

  1. Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543phase 1
  2. Anti-PSMA Antibody-drug Conjugate ARX517phase 1
  3. JNJ-86974680phase 1
  4. JNJ-87801493phase 1
  5. JNJ-64264681phase 1

and 21 more — sign in to see them all

46%
Phase 200%

Johnson & Johnson: 8 of its 56 programs at phase 2

  1. JNJ-95597528phase 2
  2. anvatabart opadotinphase 2
  3. fludarabinephase 2
  4. JNJ-64042056phase 2
  5. JNJ-88545223phase 2

and 3 more — sign in to see them all

14%
Phase 3

Jemincare: 3 of its 9 programs at phase 3

  1. JMKX003142phase 3
  2. ozureprubartphase 3
  3. KRAS G12C Inhibitor JMKX001899phase 3
33%

Johnson & Johnson: 18 of its 56 programs at phase 3

  1. amivantamabphase 3
  2. nipocalimabphase 3
  3. ramantamigphase 3
  4. icotrokinraphase 3
  5. lumateperonephase 3

and 13 more — sign in to see them all

32%
Approved, new studies

Jemincare: 1 of its 9 programs at approved, new studies

  1. sonidegibapproved, new study
11%

Johnson & Johnson: 4 of its 56 programs at approved, new studies

  1. guselkumabapproved, new study
  2. teclistamabapproved, new study
  3. ibrutinibapproved, new study
  4. Esketamineapproved, new study
7%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Jemincare3 readouts · 1 phase 3···

Jemincare, Feb ’27: 1 program whose next study reaches primary completion

  1. JMKX003142phase 3 · Feb 28 · NCT06800651
··

Jemincare, May ’27: 1 program whose next study reaches primary completion

  1. JY1001phase 1 · May 0 · NCT07848945

Jemincare, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. ozureprubartphase 3 · Jun 7 · NCT07402213
····
Johnson & Johnson26 readouts · 8 phase 3

Johnson & Johnson, Nov ’26: 1 program whose next study reaches primary completion

  1. JNJ-95597528phase 2 · Nov 19 · NCT07230860

Johnson & Johnson, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3

  1. anvatabart opadotinphase 2 · Dec 0 · NCT04829604
  2. milvexianphase 3 · Dec 8 · NCT05757869
  3. JNJ-89862175phase 1 · Dec 15 · NCT07223125
  4. nipocalimabphase 3 · Dec 15 · NCT05327114
  5. JNJ-64042056phase 2 · Dec 22 · NCT06544616

and 4 more — sign in to see them all

Johnson & Johnson, Jan ’27: 1 program whose next study reaches primary completion

  1. JNJ-86974680phase 1 · Jan 7 · NCT07319871

Johnson & Johnson, Feb ’27: 4 programs whose next study reaches primary completion, 3 in phase 3

  1. guselkumabapproved, new study · Feb 10 · NCT06260163
  2. icotrokinraphase 3 · Feb 10 · NCT06807424
  3. lazertinibphase 3 · Feb 12 · NCT04077463
  4. teclistamabapproved, new study · Feb 12 · NCT07030517

Johnson & Johnson, Mar ’27: 3 programs whose next study reaches primary completion

  1. Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387phase 1 · Mar 16 · NCT06178614
  2. deulumateperonephase 3 · Mar 16 · NCT06480383
  3. pasritamigphase 3 · Mar 31 · NCT04898634

Johnson & Johnson, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. lumateperonephase 3 · Apr 5 · NCT05850689
  2. ramantamigphase 3 · Apr 19 · NCT05652335
·

Johnson & Johnson, Jun ’27: 4 programs whose next study reaches primary completion

  1. Anti-CALRmut/Anti-CD3 Bispecific Antibody JNJ-88549968phase 1 · Jun 14 · NCT06150157
  2. Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401phase 3 · Jun 21 · NCT06095089
  3. Aticaprantphase 3 · Jun 21 · NCT07615426
  4. JNJ-88545223phase 2 · Jun 28 · NCT07321873
·

Johnson & Johnson, Aug ’27: 1 program whose next study reaches primary completion

  1. JNJ-90189892phase 1 · Aug 5 · NCT06651229
·

Johnson & Johnson, Oct ’27: 1 program whose next study reaches primary completion

  1. JNJ-88998377phase 1 · Oct 29 · NCT06470438
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Jemincare

New programs 1

  • JY1001phase 1 · first study · Sep 17 · Pain

Reached a new phase 1

  • JMKX003142phase 3 · Sep 7 · Polycystic Kidney, Autosomal Dominant

Study stopped 0

None

Primary completion later 0

None

Johnson & Johnson

New programs 1

Reached a new phase 2

Study stopped 0

None

Primary completion later 3

Where they overlap

Conditions where at least two of them have programs: 4 in all. A program counts in each condition its studies name most.

ConditionJemincareJohnson & Johnson
Carcinoma, Non-Small-Cell Lungboth · compare here

Jemincare in Carcinoma, Non-Small-Cell Lung: 1 program

  1. KRAS G12C Inhibitor JMKX001899phase 3

Their studies: Jemincare’s studies of Carcinoma, Non-Small-Cell Lung in search

Johnson & Johnson in Carcinoma, Non-Small-Cell Lung: 6 programs

  1. amivantamabphase 3
  2. lazertinibphase 3
  3. hafnium oxidephase 3
  4. anvatabart opadotinphase 2
  5. olomorasibphase 2

and 1 more — sign in to see them all

Their studies: Johnson & Johnson’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsboth · compare here

Jemincare in Breast Neoplasms: 1 program

  1. sonidegibapproved, new study

Their studies: Jemincare’s studies of Breast Neoplasms in search

Asthmaboth · compare here

Jemincare in Asthma: 1 program

  1. ozureprubartphase 3

Their studies: Jemincare’s studies of Asthma in search

Johnson & Johnson in Asthma: 1 program

  1. JNJ-95597528phase 2

Their studies: Johnson & Johnson’s studies of Asthma in search

Atrial Fibrillationboth · compare here

Jemincare in Atrial Fibrillation: 1 program

  1. Amiodaronephase 1

Their studies: Jemincare’s studies of Atrial Fibrillation in search

Johnson & Johnson in Atrial Fibrillation: 1 program

  1. milvexianphase 3

Their studies: Johnson & Johnson’s studies of Atrial Fibrillation in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetJemincareJohnson & Johnson
KRASKRAS G12C Inhibitor JMKX001899ruleolomorasib
A target, or a pathogen for a vaccine, known for: Jemincare 4 of 9 · Johnson & Johnson 33 of 56 programs (22 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Johnson & Johnson: 4).